Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function.

Vaudry H, Leprince J, Chatenet D, Fournier A, Lambert DG, Le Mével JC, Ohlstein EH, Schwertani A, Tostivint H, Vaudry D.

Pharmacol Rev. 2015;67(1):214-58. doi: 10.1124/pr.114.009480. Review.

2.

A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.

Ohlstein EH, von Keitz A, Michel MC.

Eur Urol. 2012 Nov;62(5):834-40. doi: 10.1016/j.eururo.2012.05.053. Epub 2012 Jun 5.

PMID:
22695239
3.

The grand challenges in cardiovascular drug discovery and development.

Ohlstein EH.

Front Pharmacol. 2010 Sep 23;1:125. doi: 10.3389/fphar.2010.00125. eCollection 2010. No abstract available.

4.

Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype.

Bousette N, D'Orleans-Juste P, Kiss RS, You Z, Genest J, Al-Ramli W, Qureshi ST, Gramolini A, Behm D, Ohlstein EH, Harrison SM, Douglas SA, Giaid A.

Circ Res. 2009 Sep 25;105(7):686-95, 19 p following 695. doi: 10.1161/CIRCRESAHA.107.168799. Epub 2009 Aug 20.

PMID:
19696412
5.

Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: effect of UT antagonism in ApoE knockout mice fed with Western diet.

Papadopoulos P, Bousette N, Al-Ramli W, You Z, Behm DJ, Ohlstein EH, Harrison SM, Douglas SA, Giaid A.

Atherosclerosis. 2009 Jun;204(2):395-404. doi: 10.1016/j.atherosclerosis.2008.10.044. Epub 2008 Nov 21.

PMID:
19111831
6.

IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels.

Harmar AJ, Hills RA, Rosser EM, Jones M, Buneman OP, Dunbar DR, Greenhill SD, Hale VA, Sharman JL, Bonner TI, Catterall WA, Davenport AP, Delagrange P, Dollery CT, Foord SM, Gutman GA, Laudet V, Neubig RR, Ohlstein EH, Olsen RW, Peters J, Pin JP, Ruffolo RR, Searls DB, Wright MW, Spedding M.

Nucleic Acids Res. 2009 Jan;37(Database issue):D680-5. doi: 10.1093/nar/gkn728. Epub 2008 Oct 23.

7.

Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.

Behm DJ, McAtee JJ, Dodson JW, Neeb MJ, Fries HE, Evans CA, Hernandez RR, Hoffman KD, Harrison SM, Lai JM, Wu C, Aiyar NV, Ohlstein EH, Douglas SA.

Br J Pharmacol. 2008 Oct;155(3):374-86. doi: 10.1038/bjp.2008.266. Epub 2008 Jun 30.

8.

In vivo activation of peroxisome proliferator-activated receptor-delta protects the heart from ischemia/reperfusion injury in Zucker fatty rats.

Yue TL, Nerurkar SS, Bao W, Jucker BM, Sarov-Blat L, Steplewski K, Ohlstein EH, Willette RN.

J Pharmacol Exp Ther. 2008 May;325(2):466-74. doi: 10.1124/jpet.107.135327. Epub 2008 Feb 20.

9.

Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction.

Barone FC, Willette RN, Nelson AH, Ohlstein EH, Brooks DP, Coatney RW.

Pharmacology. 2007;80(2-3):166-76. Epub 2007 Jun 4.

PMID:
17551266
10.
11.

Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease.

Bousette N, Pottinger J, Ramli W, Ohlstein EH, Dhanak D, Douglas SA, Giaid A.

Peptides. 2006 Nov;27(11):2919-26. Epub 2006 Aug 17.

PMID:
16919371
12.

Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation.

Bousette N, Hu F, Ohlstein EH, Dhanak D, Douglas SA, Giaid A.

J Mol Cell Cardiol. 2006 Aug;41(2):285-95. Epub 2006 Jun 22.

PMID:
16797584
13.

New strategies in drug discovery.

Ohlstein EH, Johnson AG, Elliott JD, Romanic AM.

Methods Mol Biol. 2006;316:1-11. Review.

PMID:
16671397
14.

A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker.

Rakowski E, Hassan GS, Dhanak D, Ohlstein EH, Douglas SA, Giaid A.

J Mol Cell Cardiol. 2005 Nov;39(5):785-91. Epub 2005 Sep 19.

PMID:
16171813
15.

Expression of urotensin-II in human coronary atherosclerosis.

Hassan GS, Douglas SA, Ohlstein EH, Giaid A.

Peptides. 2005 Dec;26(12):2464-72. Epub 2005 Jul 18.

PMID:
16026900
16.

Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.

Douglas SA, Behm DJ, Aiyar NV, Naselsky D, Disa J, Brooks DP, Ohlstein EH, Gleason JG, Sarau HM, Foley JJ, Buckley PT, Schmidt DB, Wixted WE, Widdowson K, Riley G, Jin J, Gallagher TF, Schmidt SJ, Ridgers L, Christmann LT, Keenan RM, Knight SD, Dhanak D.

Br J Pharmacol. 2005 Jul;145(5):620-35.

17.

In vivo imaging of cardiovascular endothelin receptors using the novel radiolabelled antagonist [18F]-SB209670 and positron emission tomography (microPET).

Johnström P, Fryer TD, Richards HK, Barret O, Clark JC, Ohlstein EH, Pickard JD, Davenport AP.

J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S34-8.

PMID:
15838315
19.

Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta.

Bousette N, Patel L, Douglas SA, Ohlstein EH, Giaid A.

Atherosclerosis. 2004 Sep;176(1):117-23.

PMID:
15306183
20.

New developments in the use of beta-blockers for the management of heart failure.

Ohlstein EH, Romanic AM.

Expert Opin Investig Drugs. 2004 Aug;13(8):999-1005. Review.

PMID:
15268637
21.

Techniques: Cardiovascular pharmacology and drug discovery in the 21st century.

Douglas SA, Ohlstein EH, Johns DG.

Trends Pharmacol Sci. 2004 Apr;25(4):225-33. Review.

PMID:
15063087
22.

Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion.

Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN, Ohlstein EH, Yue TL, Ma XL.

Cardiovasc Res. 2004 Apr 1;62(1):135-44.

PMID:
15023560
23.

Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia.

Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, Ma XL, Batinic-Haberle I, Willette RN, Ohlstein EH, Yue TL.

Circulation. 2003 Dec 2;108(22):2805-11. Epub 2003 Nov 10.

PMID:
14610009
24.

Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury.

Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, Brown PJ, Cui J, Thudium DT, Boyce R, Burns-Kurtis CL, Mirabile RC, Aravindhan K, Ohlstein EH.

Circulation. 2003 Nov 11;108(19):2393-9. Epub 2003 Oct 13.

PMID:
14557369
25.

Effect of human urotensin-II infusion on hemodynamics and cardiac function.

Hassan GS, Chouiali F, Saito T, Hu F, Douglas SA, Ao Z, Willette RN, Ohlstein EH, Giaid A.

Can J Physiol Pharmacol. 2003 Feb;81(2):125-8.

PMID:
12710525
26.

Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist.

Behm DJ, Herold CL, Ohlstein EH, Knight SD, Dhanak D, Douglas SA.

Br J Pharmacol. 2002 Oct;137(4):449-58.

27.

Idoxifene causes endothelium-dependent, nitric oxide-mediated vasorelaxation in male rats.

Christopher TA, Lopez BL, Stillwagon JC, Gao F, Gao E, Ma XL, Ohlstein EH, Yue TL.

Eur J Pharmacol. 2002 Jun 20;446(1-3):139-43.

PMID:
12098595
28.

Congestive heart failure and expression of myocardial urotensin II.

Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A.

Lancet. 2002 Jun 8;359(9322):1990-7.

PMID:
12076554
29.

Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma.

Shenouda A, Douglas SA, Ohlstein EH, Giaid A.

J Histochem Cytochem. 2002 Jul;50(7):885-9.

PMID:
12070267
30.

Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9.

Romanic AM, Harrison SM, Bao W, Burns-Kurtis CL, Pickering S, Gu J, Grau E, Mao J, Sathe GM, Ohlstein EH, Yue TL.

Cardiovasc Res. 2002 Jun;54(3):549-58.

PMID:
12031700
31.

Bucindolol displays intrinsic sympathomimetic activity in human myocardium.

Andreka P, Aiyar N, Olson LC, Wei JQ, Turner MS, Webster KA, Ohlstein EH, Bishopric NH.

Circulation. 2002 May 21;105(20):2429-34.

PMID:
12021232
32.
33.

p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation.

Gao F, Yue TL, Shi DW, Christopher TA, Lopez BL, Ohlstein EH, Barone FC, Ma XL.

Cardiovasc Res. 2002 Feb 1;53(2):414-22.

PMID:
11827692
34.

Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke.

Toomey JR, Valocik RE, Koster PF, Gabriel MA, McVey M, Hart TK, Ohlstein EH, Parsons AA, Barone FC.

Stroke. 2002 Feb;33(2):578-85.

PMID:
11823673
35.

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

Yue Tl TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, Ohlstein EH.

Circulation. 2001 Nov 20;104(21):2588-94.

PMID:
11714655
36.

Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction.

Willette RN, Anderson KM, Nelson AH, Olzinski AR, Woods T, Coatney RW, Aiyar N, Ohlstein EH, Barone FC.

J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17.

PMID:
11588531
37.

Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction.

Behr TM, Nerurkar SS, Nelson AH, Coatney RW, Woods TN, Sulpizio A, Chandra S, Brooks DP, Kumar S, Lee JC, Ohlstein EH, Angermann CE, Adams JL, Sisko J, Sackner-Bernstein JD, Willette RN.

Circulation. 2001 Sep 11;104(11):1292-8.

PMID:
11551882
38.

Effect of endothelin receptor antagonist on lung allograft apoptosis and NOSII expression.

Shaw MJ, Shennib H, Bousette N, Ohlstein EH, Giaid A.

Ann Thorac Surg. 2001 Aug;72(2):386-90.

PMID:
11515871
39.

Upregulated expression of human membrane type-5 matrix metalloproteinase in kidneys from diabetic patients.

Romanic AM, Burns-Kurtis CL, Ao Z, Arleth AJ, Ohlstein EH.

Am J Physiol Renal Physiol. 2001 Aug;281(2):F309-17.

40.

Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban.

Erhardt JA, Ohlstein EH, Toomey JR, Gabriel MA, Willette RN, Yue TL, Barone FC, Parsons AA.

Thromb Res. 2001 Jul 15;103(2):143-8. No abstract available.

PMID:
11457472
41.

Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.

Barone FC, Coatney RW, Chandra S, Sarkar SK, Nelson AH, Contino LC, Brooks DP, Campbell WG Jr, Ohlstein EH, Willette RN.

Cardiovasc Res. 2001 Jun;50(3):525-37.

PMID:
11376628
42.

Therapeutic modulation of transcription factor activity.

Emery JG, Ohlstein EH, Jaye M.

Trends Pharmacol Sci. 2001 May;22(5):233-40. Review.

PMID:
11339974
43.
44.

Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia.

Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, Legos JJ, Erhardt JA, Ohlstein EH, Hunter AJ, Harrison DC, Philpott K, Smith BR, Adams JL, Parsons AA.

Med Res Rev. 2001 Mar;21(2):129-45. Review.

PMID:
11223862
45.

Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit.

Romanic AM, Burns-Kurtis CL, Gout B, Berrebi-Bertrand I, Ohlstein EH.

Life Sci. 2001 Jan 5;68(7):799-814.

PMID:
11205871
46.

SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.

Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, White RF, McVey MJ, Legos JJ, Erhardt JA, Nelson AH, Ohlstein EH, Hunter AJ, Ward K, Smith BR, Adams JL, Parsons AA.

J Pharmacol Exp Ther. 2001 Feb;296(2):312-21.

47.

Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries.

Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Berry C, Kirk A, Richardson M, MacLean MR.

Am J Physiol Heart Circ Physiol. 2001 Feb;280(2):H925-8.

48.

Endothelial protective and antishock effects of a selective estrogen receptor modulator in rats.

Ma XL, Gao F, Chen J, Christopher TA, Lopez BL, Ohlstein EH, Yue T.

Am J Physiol Heart Circ Physiol. 2001 Feb;280(2):H876-84.

49.

Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey.

Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN.

Br J Pharmacol. 2000 Dec;131(7):1262-74.

Supplemental Content

Loading ...
Support Center